Skip to main content

Table 1 Cohort characteristics

From: Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials

Studies Cases Mean age Female patient Surgical methods TXA intervention Prophylactic antithrombotic Transfusion trigger follow-up
(E/C) (E/C) (E/C)
Huang 2014 [7] 92/92 65.4/64.7 55/62 TKA E:1.5 g topical injection +1.5 g i.v. LMWH, 6000 IU HB less than 7 g/dL 1–3 months
C:3 g i.v.
Nielsen 2016 [8] 30/30 65.5/63.2 17/15 TKA E:3 g topical injection + 1 g i.v. Rivaroxaban, 10 mg HB less than 7.5 g/dL 3 months
C:3 g i.v.
Jain 2016 [12] 59/60 68.3/70.0 39/36 TKA E:pre-op.15 mg/kg i.v. + post-op.10 mg/kg i.v. + 2 g topical injection Aspirin, 75 mg HB less than 7 g/dL NS
C:pre-op.15 mg/kg i.v. + post-op.10 mg/kg i.v
Xie 2016 [11] 70/70 60.5/59.5 48/50 THA E:1 g topical injection + 2 g i.v. Enoxaparin, 6000 IU HB less than 7 g/dL 1–3 months
C:1.5 g i.v.
Wu 2016 [10] 42/42 60.1/59.5 19/21 Reversion THA E:3 g topical injection +15 mg/kg i.v. LMWH, 6000 IU HB less than 8 g/dL 3 months
C:15 mg/kg i.v.
Song 2016 [9] 50/50 70.8/69.2 43/44 TKA E: 1.5 g topical injection +10 mg/kg i.v.
C:E:pre-op.10 mg/kg i.v. + post-op.10 mg/kg
Not performed HB less than 8 g/dL 1 month
  1. E experiment group, C control group, i.v. intravenous injection, LMWH low-molecular-weight heparin, HB haemoglobin, pre-op preoperative, post-op postoperative, NS not stated